在患有重症慢性病的患者中,冠状动脉疾病和皮肤穿冠状动脉干预
Doosup Shin1, Keyvan Karimi Galougahi1, Mandeep Singh2
1Department of Cardiology, St Francis Hospital and Heart Center, Roslyn, New York, USA.
Progress in cardiovascular diseases
|January 6, 2025
概括
慢性病 (CKD) 患者的冠状动脉疾病 (CAD) 存在风险. 零对比性皮肤冠状动脉干预 (PCI) 为这些高危人群提供了更安全的替代方案,改善了结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 干预心脏病学 干预心脏病学
背景情况:
- 冠状动脉疾病 (CAD) 是慢性病 (CKD) 患者的主要死亡原因.
- 慢性病患者通常具有非典型的CAD症状,并面临诸如对比诱导病等程序性风险.
- 害怕损伤可能会导致延迟必要的干预,称为"病".
研究的目的:
- 审查在CKD患者中诊断和管理CAD的挑战.
- 探索传统诊断和干预方法的局限性.
- 引入新兴的对比节省技术用于CKD中的CAD管理.
主要方法:
- 对CKD中CAD的当前文献的综述.
- 讨论临床表现和诊断局限性.
- 超低对比度血管学 (ULCA) 和零对比度皮肤冠状动脉干预 (PCI) 的概述.
主要成果:
- ULCA和零对比的PCI证明了安全性和可行性,即使在复杂的情况下.
- 这些技术可以最大限度地减少或消除对比的暴露,从而降低脏风险.
- 新兴的对比节约方法对高风险的CKD患者来说是有前途的.
结论:
- 零对比性PCI是高风险CKD患者重血管化的潜在重要策略.
- 这些技术提高了手术安全性,同时保持了治疗效果.
- 对比节约干预的进展对于改善CKD的CAD管理至关重要.
相关概念视频
Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Dialysis
261
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
261
Renal Failure: Dose Adjustments
62
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338


